LncRNAs Roles in Chemoresistance of Cancer Cells

doi:10.2174/1566524021666211027090515
摘要

癌症是世界范围内一个重要的健康问题。癌症治疗是多方面的，耐药性仍然是治疗该病患者的主要限制因素。尽管已经广泛研究了抗癌药物耐药性的机制，但参与该过程的非编码RNA（ncRNA）的大量生物信号通路尚未完全了解。长链非编码 RNA (lncRNA) 是一种最小长度为 200 个核苷酸的转录本，其编码蛋白质的潜力有限。已经评估了这些 RNA 分子与几种病理过程相关的作用，包括肿瘤形成和进展。最近越来越多的证据表明，非编码 RNA (ncRNA)，尤其是长链非编码 RNA，在许多细胞和基因组过程中发挥着重要作用，并且由于它们在调节特定基因方面的潜力，它们也与耐药性有关。在这篇综述中，我们回顾了有关 lncRNA 特征的文献，它们在与化疗耐药相关的基因表达中的调节作用，以及这些 RNA 作为靶向治疗癌症个体化治疗的潜力。
关键词: 非编码 RNA、长链非编码 RNA、耐药性、个性化治疗、癌症、上皮间质转化。
« Previous Next »
[1] 
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin  2015; 65(2): 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787] 
[2] 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593] 
[3] 
Liu K, Gao L, Ma X, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer  2020; 19(1): 54.
[http://dx.doi.org/10.1186/s12943-020-01162-0] [PMID:  32164712] 
[4] 
Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol  2016; 43(8): 723-37.
[http://dx.doi.org/10.1111/1440-1681.12581] [PMID:  27097837] 
[5] 
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene  2003; 22(47): 7265-79.
[http://dx.doi.org/10.1038/sj.onc.1206933] [PMID:  14576837] 
[6] 
Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol  2013; 85(9): 1219-26.
[http://dx.doi.org/10.1016/j.bcp.2013.02.017] [PMID:  23435357] 
[7] 
Lønning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med  2004; 10(3): 113-8.
[http://dx.doi.org/10.1016/j.molmed.2004.01.005] [PMID:  15102353] 
[8] 
Ayers D, Vandesompele J. Influence of microRNAs and long non-coding RNAs in cancer chemoresistance. Genes (Basel)  2017; 8(3): 95.
[http://dx.doi.org/10.3390/genes8030095] [PMID:  28273813] 
[9] 
Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer  2011; 10(1): 38.
[http://dx.doi.org/10.1186/1476-4598-10-38] [PMID:  21489289] 
[10] 
Zhu Q-N, Wang G, Guo Y, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget  2017; 8(54): 91990-2003.
[http://dx.doi.org/10.18632/oncotarget.21121] [PMID:  29190892] 
[11] 
Kaushik SB, Kaushik N. Non-coding RNAs in skin cancers: An update. Noncoding RNA Res  2016; 1(1): 83-6.
[12] 
Nikpayam E, Tasharrofi B, Sarrafzadeh S, Ghafouri-Fard S. The role of long non-coding RNAs in ovarian cancer. Iran Biomed J  2017; 21(1): 3-15.
[http://dx.doi.org/10.18869/acadpub.ibj.21.1.3] [PMID:  27664137] 
[13] 
Xiong G, Feng M, Yang G, et al. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Lett  2017; 397: 94-102.
[http://dx.doi.org/10.1016/j.canlet.2017.02.020] [PMID:  28254409] 
[14] 
Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene  2012; 31(43): 4577-87.
[http://dx.doi.org/10.1038/onc.2011.621] [PMID:  22266873] 
[15] 
Röhr C, Kerick M, Fischer A, et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One  2013; 8(7): e67461.
[http://dx.doi.org/10.1371/journal.pone.0067461] [PMID:  23874421] 
[16] 
Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell  2013; 154(1): 26-46.
[http://dx.doi.org/10.1016/j.cell.2013.06.020] [PMID:  23827673] 
[17] 
Wang Y, Qian CY, Li XP, et al. Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer. Sci Rep  2015; 5: 11671.
[http://dx.doi.org/10.1038/srep11671] [PMID:  26159226] 
[18] 
Peng Z, Liu C, Wu M. New insights into long noncoding RNAs and their roles in glioma. Mol Cancer  2018; 17(1): 61.
[http://dx.doi.org/10.1186/s12943-018-0812-2] [PMID:  29458374] 
[19] 
Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem  2012; 81: 145-66.
[http://dx.doi.org/10.1146/annurev-biochem-051410-092902] [PMID:  22663078] 
[20] 
Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res  2018; 3(3): 108-17.
[http://dx.doi.org/10.1016/j.ncrna.2018.03.001] [PMID:  30175284] 
[21] 
Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol  2013; 10(6): 925-33.
[http://dx.doi.org/10.4161/rna.24604] [PMID:  23696037] 
[22] 
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom Prot Bioinf  2016; 14(1): 42-54.
[http://dx.doi.org/10.1016/j.gpb.2015.09.006] [PMID:  26883671] 
[23] 
Pandey RR, Mondal T, Mohammad F, et al. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell  2008; 32(2): 232-46.
[http://dx.doi.org/10.1016/j.molcel.2008.08.022] [PMID:  18951091] 
[24] 
Kallen AN, Zhou XB, Xu J, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell  2013; 52(1): 101-12.
[http://dx.doi.org/10.1016/j.molcel.2013.08.027] [PMID:  24055342] 
[25] 
Chen N, Guo D, Xu Q, et al. Long non-coding RNA FEZF1-AS1 facilitates cell proliferation and migration in colorectal carcinoma. Oncotarget  2016; 7(10): 11271-83.
[http://dx.doi.org/10.18632/oncotarget.7168] [PMID:  26848625] 
[26] 
Yu J, Han Z, Sun Z, Wang Y, Zheng M, Song C. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway. J Exp Clin Cancer Res  2018; 37(1): 222.
[http://dx.doi.org/10.1186/s13046-018-0896-y] [PMID:  30201010] 
[27] 
Carlevaro-Fita J, Lanzós A, Feuerbach L, et al. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol  2020; 3(1): 56.
[http://dx.doi.org/10.1038/s42003-019-0741-7] [PMID:  32024996] 
[28] 
Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol  2017; 1008: 199-222.
[http://dx.doi.org/10.1007/978-981-10-5203-3_7] [http://dx.doi.org/10.1007/978-981-10-5203-3_7] 
[29] 
Petrovics G, Zhang W, Makarem M, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene  2004; 23(2): 605-11.
[http://dx.doi.org/10.1038/sj.onc.1207069] [PMID:  14724589] 
[30] 
Ginger MR, Shore AN, Contreras A, et al. A noncoding RNA is a potential marker of cell fate during mammary gland development. Proc Natl Acad Sci USA  2006; 103(15): 5781-6.
[http://dx.doi.org/10.1073/pnas.0600745103] [PMID:  16574773] 
[31] 
Gejman R, Batista DL, Zhong Y, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab  2008; 93(10): 4119-25.
[http://dx.doi.org/10.1210/jc.2007-2633] [PMID:  18628527] 
[32] 
Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med  2006; 12(11): 1294-300.
[http://dx.doi.org/10.1038/nm1491] [PMID:  17057710] 
[33] 
Crijns AP, Fehrmann RS, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med  2009; 6(2): e24.
[http://dx.doi.org/10.1371/journal.pmed.1000024] [PMID:  19192944] 
[34] 
Etemadmoghadam D, deFazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res  2009; 15(4): 1417-27.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1564] [PMID:  19193619] 
[35] 
Raguz S, Yagüe E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer  2008; 99(3): 387-91.
[http://dx.doi.org/10.1038/sj.bjc.6604510] [PMID:  18665178] 
[36] 
Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol  2006; 207(3): 571-81.
[http://dx.doi.org/10.1002/jcp.20515] [PMID:  16250021] 
[37] 
Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat  2007; 10(1-2): 59-67.
[http://dx.doi.org/10.1016/j.drup.2007.02.002] [PMID:  17350322] 
[38] 
Malek E, Jagannathan S, Driscoll JJ. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget  2014; 5(18): 8027-38.
[http://dx.doi.org/10.18632/oncotarget.2469] [PMID:  25275300] 
[39] 
Fan Y, Shen B, Tan M, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J  2014; 281(7): 1750-8.
[http://dx.doi.org/10.1111/febs.12737] [PMID:  24495014] 
[40] 
Wang H, Guan Z, He K, Qian J, Cao J, Teng L. LncRNA UCA1 in anti-cancer drug resistance. Oncotarget  2017; 8(38): 64638-50.
[http://dx.doi.org/10.18632/oncotarget.18344] [PMID:  28969100] 
[41] 
Hu Y, Zhu QN, Deng JL, Li ZX, Wang G, Zhu YS. Emerging role of long non-coding RNAs in cisplatin resistance. OncoTargets Ther  2018; 11: 3185-94.
[http://dx.doi.org/10.2147/OTT.S158104] [PMID:  29881292] 
[42] 
Martin T, Jiang W. Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry-Anti-cancer agents). Anticancer Agents Med Chem  2010; 10(1): 1.
[43] 
Paškevičiūtė M, Petrikaitė V. Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades. Drug Deliv Transl Res  2019; 9(1): 379-93.
[http://dx.doi.org/10.1007/s13346-018-0584-7] [PMID:  30194528] 
[44] 
Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics  2009; 3(3): 281-90.
[http://dx.doi.org/10.1186/1479-7364-3-3-281] [PMID:  19403462] 
[45] 
Chen QN, Wei CC, Wang ZX, Sun M. Long non-coding RNAs in anti-cancer drug resistance. Oncotarget  2017; 8(1): 1925-36.
[http://dx.doi.org/10.18632/oncotarget.12461] [PMID:  27713133] 
[46] 
Eisses JF, Kaplan JH. Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem  2002; 277(32): 29162-71.
[http://dx.doi.org/10.1074/jbc.M203652200] [PMID:  12034741] 
[47] 
Hang Q, Sun R, Jiang C, Li Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anticancer Drugs  2015; 26(6): 632-40.
[http://dx.doi.org/10.1097/CAD.0000000000000227] [PMID:  25763542] 
[48] 
Fang Z, Chen W, Yuan Z, Liu X, Jiang H. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother  2018; 101: 536-42.
[http://dx.doi.org/10.1016/j.biopha.2018.02.130] [PMID:  29505924] 
[49] 
Cui Y, Li G, Zhang X, Dai F, Zhang R. Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer. Oncol Lett  2018; 16(4): 4821-8.
[http://dx.doi.org/10.3892/ol.2018.9293] [PMID:  30250547] 
[50] 
Zhu J, Zhang R, Yang D, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem  2018; 51(1): 113-28.
[http://dx.doi.org/10.1159/000495168] [PMID:  30439718] 
[51] 
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem  2018; 48(1): 16-28.
[http://dx.doi.org/10.1159/000491659] [PMID:  30001527] 
[52] 
Carke M. Cancer Stem Cells-Perspectives on current status and future directions. AACR Workshop on Cancer Stem Cells Cancer Res.  9339-44.
[53] 
Lee MY, Giraddi RR, Tam WL. Cancer Stem Cells: Concepts, Challenges, and Opportunities for Cancer Therapy.Chimera Research.  Springer 2019; pp. 43-66.
[http://dx.doi.org/10.1007/978-1-4939-9524-0_4] 
[54] 
Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer  2003; 3(12): 895-902.
[http://dx.doi.org/10.1038/nrc1232] [PMID:  14737120] 
[55] 
Zhang L, Jiao M, Li L, et al. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol  2012; 138(4): 675-86.
[http://dx.doi.org/10.1007/s00432-011-1146-2] [PMID:  22237455] 
[56] 
Su YJ, Lai HM, Chang YW, Chen GY, Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J  2011; 30(15): 3186-99.
[http://dx.doi.org/10.1038/emboj.2011.211] [PMID:  21701559] 
[57] 
Metzger E, Stepputtis SS, Strietz J, et al. KDM4 Inhibition Targets Breast Cancer Stem-like Cells. Cancer Res  2017; 77(21): 5900-12.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1754] [PMID:  28883001] 
[58] 
Mao XG, Guo G, Wang P, et al. Maintenance of critical properties of brain tumor stem-like cells after cryopreservation. Cell Mol Neurobiol  2010; 30(5): 775-86.
[http://dx.doi.org/10.1007/s10571-010-9505-0] [PMID:  20155395] 
[59] 
Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev  2004; 18(10): 1131-43.
[http://dx.doi.org/10.1101/gad.294104] [PMID:  15155580] 
[60] 
Elzamly S, Badri N, Padilla O, et al. Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy. Breast Cancer (Auckl)  2018; 12: 1178223418788074.
[http://dx.doi.org/10.1177/1178223418788074] [PMID:  30083055] 
[61] 
Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell  2016; 166(1): 21-45.
[http://dx.doi.org/10.1016/j.cell.2016.06.028] [PMID:  27368099] 
[62] 
Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell  2017; 168(4): 670-91.
[http://dx.doi.org/10.1016/j.cell.2016.11.037] [PMID:  28187288] 
[63] 
Jolly MK, Boareto M, Huang B, et al. Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. Front Oncol  2015; 5: 155.
[http://dx.doi.org/10.3389/fonc.2015.00155] [PMID:  26258068] 
[64] 
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA  2003; 100(7): 3983-8.
[http://dx.doi.org/10.1073/pnas.0530291100] [PMID:  12629218] 
[65] 
Alisi A, Cho WC, Locatelli F, Fruci D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int J Mol Sci  2013; 14(12): 24706-25.
[http://dx.doi.org/10.3390/ijms141224706] [PMID:  24351843] 
[66] 
Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med  2013; 2(1): 3.
[http://dx.doi.org/10.1186/2001-1326-2-3] [PMID:  23369605] 
[67] 
Eyre R, Harvey I, Stemke-Hale K, Lennard TW, Tyson-Capper A, Meeson AP. Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population. Tumour Biol  2014; 35(10): 9879-92.
[http://dx.doi.org/10.1007/s13277-014-2277-2] [PMID:  24993095] 
[68] 
Zhang Y, Tang X, Shi M, Wen C, Shen B. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun  2017; 483(2): 816-22.
[http://dx.doi.org/10.1016/j.bbrc.2016.12.167] [PMID:  28034748] 
[69] 
Yin T, Wei H, Gou S, et al. Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci  2011; 12(3): 1595-604.
[http://dx.doi.org/10.3390/ijms12031595] [PMID:  21673909] 
[70] 
Han T, Hu H, Zhuo M, et al. Long non-coding RNA: an emerging paradigm of pancreatic cancer. Curr Mol Med  2016; 16(8): 702-9.
[http://dx.doi.org/10.2174/1566524016666160927095812] [PMID:  27686798] 
[71] 
Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res  2009; 15(12): 4234-41.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1479] [PMID:  19509181] 
[72] 
Zhao J. Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther  2016; 160: 145-58.
[http://dx.doi.org/10.1016/j.pharmthera.2016.02.008] [PMID:  26899500] 
[73] 
Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther  2012; 19(11): 723-30.
[http://dx.doi.org/10.1038/cgt.2012.58] [PMID:  22975591] 
[74] 
Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA Repair (Amst)  2016; 45: 25-33.
[http://dx.doi.org/10.1016/j.dnarep.2016.06.003] [PMID:  27427176] 
[75] 
Dou J, Ni Y, He X, et al. Decreasing lncRNA HOTAIR expression inhibits human colorectal cancer stem cells. Am J Transl Res  2016; 8(1): 98-108.
[PMID:  27069543] 
[76] 
Yu X, Li Z, Zheng H, Chan MT, Wu WK. NEAT1: A novel cancer-related long non-coding RNA. Cell Prolif  2017; 50(2)
[http://dx.doi.org/10.1111/cpr.12329] [PMID:  28105699] 
[77] 
Heery R, Finn SP, Cuffe S, Gray SG. Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. Cancers (Basel)  2017; 9(4): E38.
[http://dx.doi.org/10.3390/cancers9040038] [PMID:  28430163] 
[78] 
Kim G, Ouzounova M, Quraishi AA, et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene  2015; 34(6): 671-80.
[http://dx.doi.org/10.1038/onc.2014.4] [PMID:  24531711] 
[79] 
Zhou QX, Jiang XM, Wang ZD, Li CL, Cui YF. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis. Med Oncol  2015; 32(4): 105.
[http://dx.doi.org/10.1007/s12032-015-0553-7] [PMID:  25744243] 
[80] 
Jun W. Am Surg  2019; 85(6): 645-53.
[http://dx.doi.org/10.1177/000313481908500630] [PMID:  31267907] 
[81] 
Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget  2015; 6(26): 22513-25.
[http://dx.doi.org/10.18632/oncotarget.4154] [PMID:  26068968] 
[82] 
Jiao F, Hu H, Yuan C, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep  2014; 32(6): 2485-92.
[http://dx.doi.org/10.3892/or.2014.3518] [PMID:  25269958] 
[83] 
Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules  2016; 21(7): E965.
[http://dx.doi.org/10.3390/molecules21070965] [PMID:  27455225] 
[84] 
Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol  2007; 8(9): 741-52.
[http://dx.doi.org/10.1038/nrm2239] [PMID:  17717517] 
[85] 
Wang C-Y, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med  1999; 5(4): 412-7.
[http://dx.doi.org/10.1038/7410] [PMID:  10202930] 
[86] 
Heere-Ress E, Thallinger C, Lucas T, et al. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer  2002; 99(1): 29-34.
[http://dx.doi.org/10.1002/ijc.10248] [PMID:  11948488] 
[87] 
Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E, et al. LncRNAs as regulators of autophagy and drug resistance in colorectal cancer. Front Oncol  2019; 9: 1008.
[http://dx.doi.org/10.3389/fonc.2019.01008] [PMID:  31632922] 
[88] 
Liu J, Wan L, Lu K, et al. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS One  2015; 10(5): e0114586.
[http://dx.doi.org/10.1371/journal.pone.0114586] [PMID:  25992654] 
[89] 
Li Y, Lv S, Ning H, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother  2018; 108: 1775-82.
[http://dx.doi.org/10.1016/j.biopha.2018.09.181] [PMID:  30372881] 
[90] 
Li W, Zhai L, Wang H, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget  2016; 7(19): 27778-86.
[http://dx.doi.org/10.18632/oncotarget.8413] [PMID:  27034004] 
[91] 
Si X, Zang R, Zhang E, et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget  2016; 7(49): 81452-62.
[http://dx.doi.org/10.18632/oncotarget.13263] [PMID:  27845892] 
[92] 
Jiang M, Huang O, Xie Z, et al. A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol  2014; 87(2): 254-83.
[http://dx.doi.org/10.1016/j.bcp.2013.10.020] [PMID:  24184505] 
[93] 
Tsang S, Patel T, Yustein JT. Long non-coding RNAs regulation of therapeutic resistance. Mol Cancer  2020; 19: 54.
[http://dx.doi.org/10.20517/cdr.2019.58] 
[94] 
Zhu L, Zhu Y, Han S, et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis  2019; 10(6): 383.
[http://dx.doi.org/10.1038/s41419-019-1585-2] [PMID:  31097692] 
[95] 
Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res  2009; 15(24): 7479-91.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0636] [PMID:  20008848] 
[96] 
Li Y, Ye Y, Feng B, Qi Y. Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J Cell Biochem  2017; 118(12): 4498-507.
[http://dx.doi.org/10.1002/jcb.26107] [PMID:  28464252] 
[97] 
Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol  2009; 4: 127-50.
[http://dx.doi.org/10.1146/annurev.pathol.4.110807.092311] [PMID:  18767981] 
[98] 
Li W, Dong X, He C, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res  2019; 38(1): 183.
[http://dx.doi.org/10.1186/s13046-019-1177-0] [PMID:  31053148] 
[99] 
Zhuang J, Shen L, Yang L, et al. TGFβ1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics  2017; 7(12): 3053-67.
[http://dx.doi.org/10.7150/thno.19542] [PMID:  28839463] 
[100] 
Su M, Wang H, Wang W, et al. LncRNAs in DNA damage response and repair in cancer cells. Acta Biochim Biophys Sin (Shanghai)  2018; 50(5): 433-9.
[http://dx.doi.org/10.1093/abbs/gmy022] [PMID:  29554194] 
[101] 
Wan G, Hu X, Liu Y, et al. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J  2013; 32(21): 2833-47.
[http://dx.doi.org/10.1038/emboj.2013.221] [PMID:  24097061] 
[102] 
Sharma V, Khurana S, Kubben N, et al. A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep  2015; 16(11): 1520-34.
[http://dx.doi.org/10.15252/embr.201540437] [PMID:  26412854] 
[103] 
Liu J, Sun X, Zhu H, Qin Q, Yang X, Sun X. Long noncoding RNA POU6F2-AS2 is associated with oesophageal squamous cell carcinoma. J Biochem  2016; 160(4): 195-204.
[http://dx.doi.org/10.1093/jb/mvw025] [PMID:  27033944] 
[104] 
Kalvapalle PB. Functional analysis of tyrosine kinase mutants in cancer. Johns Hopkins University 2016.
[105] 
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther  2016; 38(7): 1551-66.
[http://dx.doi.org/10.1016/j.clinthera.2016.03.026] [PMID:  27158009] 
[106] 
Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget  2016; 7(31): 49948-60.
[http://dx.doi.org/10.18632/oncotarget.10521] [PMID:  27409677] 
[107] 
Herling A, König M, Bulik S, Holzhütter HG. Enzymatic features of the glucose metabolism in tumor cells. FEBS J  2011; 278(14): 2436-59.
[http://dx.doi.org/10.1111/j.1742-4658.2011.08174.x] [PMID:  21564549] 
[108] 
Rochat B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr Cancer Drug Targets  2009; 9(5): 652-74.
[http://dx.doi.org/10.2174/156800909789056999] [PMID:  19686091] 
[109] 
Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics  2018; 8(14): 3932-48.
[http://dx.doi.org/10.7150/thno.25541] [PMID:  30083271] 
[110] 
Liu LC, Wang YL, Lin PL, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer  2019; 145(9): 2478-87.
[http://dx.doi.org/10.1002/ijc.32319] [PMID:  30963568] 
[111] 
Xiong G, Liu C, Yang G, et al. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol  2019; 12(1): 97.
[http://dx.doi.org/10.1186/s13045-019-0777-7] [PMID:  31514732] 
[112] 
Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene  2007; 26(33): 4877-81.
[http://dx.doi.org/10.1038/sj.onc.1210266] [PMID:  17297456] 
[113] 
Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res  2014; 12(10): 1377-87.
[http://dx.doi.org/10.1158/1541-7786.MCR-13-0636] [PMID:  24874432] 
[114] 
Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun  2015; 462(3): 227-32.
[http://dx.doi.org/10.1016/j.bbrc.2015.04.121] [PMID:  25956062] 
[115] 
Ren K, Xu R, Huang J, Zhao J, Shi W. Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma. Cancer Chemother Pharmacol  2017; 80(2): 243-50.
[http://dx.doi.org/10.1007/s00280-017-3356-z] [PMID:  28600629] 
[116] 
Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother  2018; 99: 832-8.
[http://dx.doi.org/10.1016/j.biopha.2018.01.130] [PMID:  29710482] 
[117] 
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol  2014; 34(17): 3182-93.
[http://dx.doi.org/10.1128/MCB.01580-13] [PMID:  24958102] 
[118] 
Lan W-G, Xu DH, Xu C, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep  2016; 36(1): 263-70.
[http://dx.doi.org/10.3892/or.2016.4771] [PMID:  27121324] 
[119] 
Luo Y, Yang J, Yu J, et al. Long non-coding RNAs: Emerging roles in the immunosuppressive tumor microenvironment. Front Oncol  2020; 10: 48.
[http://dx.doi.org/10.3389/fonc.2020.00048] [PMID:  32083005] 
[120] 
Zhou Y, Zhu Y, Xie Y, Ma X. The Role of Long Non-coding RNAs in Immunotherapy Resistance. Front Oncol  2019; 9: 1292.
[http://dx.doi.org/10.3389/fonc.2019.01292] [PMID:  31850199] 
[121] 
Rapicavoli NA.  A mammalian pseudogene lncRNA at the
interface of inflammation and anti-inflammatory therapeutics.
elife 2013; 2: e00762.
[http://dx.doi.org/10.7554/eLife.00762] 
[122] 
Song B, Guan Z, Liu F, Sun D, Wang K, Qu H. Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. Biochem Biophys Res Commun  2015; 464(3): 807-13.
[http://dx.doi.org/10.1016/j.bbrc.2015.07.040] [PMID:  26187665] 
[123] 
Wang C-J, Zhu CC, Xu J, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer  2019; 18(1): 115.
[http://dx.doi.org/10.1186/s12943-019-1032-0] [PMID:  31272462] 
[124] 
Dang S, Malik A, Chen J, et al. LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1. OncoTargets Ther  2020; 13: 8547-56.
[http://dx.doi.org/10.2147/OTT.S251625] [PMID:  32943878] 
[125] 
Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm  2013; 10(1): 337-52.
[http://dx.doi.org/10.1021/mp3004622] [PMID:  23215027] 
[126] 
Zhou J, Yang L, Zhong T, et al. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosyl-homocysteine hydrolase. Nat Commun  2015; 6(1): 10221.
[http://dx.doi.org/10.1038/ncomms10221] [PMID:  26687445] 
[127] 
Di Ruscio A, Ebralidze AK, Benoukraf T, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature  2013; 503(7476): 371-6.
[http://dx.doi.org/10.1038/nature12598] [PMID:  24107992] 
[128] 
Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature  2010; 464(7291): 1071-6.
[http://dx.doi.org/10.1038/nature08975] [PMID:  20393566] 
[129] 
Song Y, Wang R, Li LW, et al. Long non-coding RNA HOTAIR mediates the switching of histone H3 lysine 27 acetylation to methylation to promote epithelial-to-mesenchymal transition in gastric cancer. Int J Oncol  2019; 54(1): 77-86.
[PMID:  30431069] 
[130] 
Beckedorff FC, Amaral MS, Deocesano-Pereira C, Verjovski-Almeida S. Long non-coding RNAs and their implications in cancer epigenetics. Biosci Rep  2013; 33(4): e00061.
[http://dx.doi.org/10.1042/BSR20130054] [PMID:  23875687] 
[131] 
Kong R, Zhang EB, Yin DD, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer  2015; 14(1): 82.
[http://dx.doi.org/10.1186/s12943-015-0355-8] [PMID:  25890171] 
[132] 
Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget  2016; 7(1): 241-54.
[http://dx.doi.org/10.18632/oncotarget.6280] [PMID:  26540633] 
[133] 
Chen R, Li X, He B, Hu W. MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep  2017; 15(3): 1326-34.
[http://dx.doi.org/10.3892/mmr.2017.6149] [PMID:  28138700] 
[134] 
Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. Biomed Pharmacother  2019; 118: 109129.
[http://dx.doi.org/10.1016/j.biopha.2019.109129] [PMID:  31326791] 
[135] 
Grelet S, Link LA, Howley B, et al. A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol  2017; 19(9): 1105-15.
[http://dx.doi.org/10.1038/ncb3595] [PMID:  28825698] 
[136] 
Gougelet A, Desbois-Mouthon C. Non-coding RNAs open a new chapter in liver cancer treatment. Clin Res Hepatol Gastroenterol  2019; 43(6): 630-7.
[http://dx.doi.org/10.1016/j.clinre.2019.07.005] [PMID:  31401041] 
[137] 
Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene  2011; 30(16): 1956-62.
[http://dx.doi.org/10.1038/onc.2010.568] [PMID:  21151178] 
[138] 
Chung S, Nakagawa H, Uemura M, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci  2011; 102(1): 245-52.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01737.x] [PMID:  20874843] 
[139] 
Wang X-S, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res  2006; 12(16): 4851-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-0134] [PMID:  16914571] 
[140] 
Zhou Q, Liu J, Quan J, Liu W, Tan H, Li W. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: A systematic review and meta-analysis. Gene  2018; 668: 77-86.
[http://dx.doi.org/10.1016/j.gene.2018.05.054] [PMID:  29777909] 
[141] 
Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene  2009; 28(2): 195-208.
[http://dx.doi.org/10.1038/onc.2008.373] [PMID:  18836484] 
[142] 
Qu X, Li Y, Wang L, Yuan N, Ma M, Chen Y. LncRNA SNHG8 accelerates proliferation and inhibits apoptosis in HPV-induced cervical cancer through recruiting EZH2 to epigenetically silence RECK expression. J Cell Biochem  2020; 121(10): 4120-9.
[http://dx.doi.org/10.1002/jcb.29646] [PMID:  31961005] 
[143] 
Augoff K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer  2012; 11(1): 5.
[http://dx.doi.org/10.1186/1476-4598-11-5] [PMID:  22289355] 
[144] 
Quan J, Pan X, Zhao L, et al. LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis. OncoTargets Ther  2018; 11: 6415-24.
[http://dx.doi.org/10.2147/OTT.S167853] [PMID:  30323619] 
[145] 
Chen F, Yin S, Zhu J, et al. lncRNA DGCR5 acts as a tumor suppressor in papillary thyroid carcinoma via sequestering miR-2861. Exp Ther Med  2019; 17(1): 895-900.
[PMID:  30651878] 
Rights & Permissions Print Cite
Article Metrics
14
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1566524021666211027090515	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666
当代分子医药

LncRNAs 在癌细胞化学抗性中的作用

摘要

当代分子医药

LncRNAs 在癌细胞化学抗性中的作用

摘要 Play Pause

Related Journals

Related Books

摘要
